Intravenous Iron Drugs - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

The intravenous iron drugs market size is expected to grow from USD 3.31 billion in 2025 to USD 3.59 billion in 2026 and is forecast to reach USD 5.37 billion by 2031 at 8.40% CAGR over 2026-2031. This report is Segmented by Product Type (Ferric Carboxymaltose, and More), Indication (Chronic Kidney Disease, Inflammatory Bowel Disease, and More), End-User (Hospitals, and More), Distribution Channel (Direct Tenders, and More), and Geography (North America, Europe, Asia-Pacific, Middle East & Africa, South America). The Market Forecasts are Provided in Terms of Value (USD).

Global Intravenous Iron Drugs Market Trends and Insights

Escalating Global Iron-Deficiency Anemia Burden Across CKD, IBD, Oncology & HF Populations

Clinical audits show iron deficiency in 37-61% of HF patients, and meta-analysis confirms that IV iron lowers cardiovascular mortality by 13% compared with placebo. Renal guidelines mandate regular iron supplementation for 92% of dialysis recipients, while CKD prevalence growth sustains baseline demand. China still reports 79.6 million iron-deficient adults even after a 40.86% fall in dietary deficiency rates since 1990. Functional deficiency in cancer adds incremental volume because inflammation blocks gut absorption. Collectively, these disease pools secure long-run volume growth across nephrology, cardiology and oncology clinics.

Growing Clinical Preference for Intravenous Iron to Overcome Poor Oral Absorption & Adherence

Consensus statements published in 2024 indicate that oral ferrous salts often fail to normalize ferritin or improve 6-minute-walk distance in HF with reduced ejection fraction. The IRONMAN trial showed the greatest benefit among patients with transferrin saturation below 20%. Real-world Japanese data in 632,200 cases reported a 3.20 g/dL hemoglobin rise with ferric carboxymaltose versus 1.70 g/dL for oral iron at week 12. High discontinuation rates tied to gastrointestinal intolerance further tilt prescribers toward parenteral therapy, cementing demand across chronic disease cohorts.

Safety Concerns (Hypersensitivity, Hypophosphatemia) Limiting Uptake of High-Dose Formulations

Ferric carboxymaltose triggers hypophosphatemia in more than 70% of recipients within five weeks by elevating FGF-23, risking cardiac dysfunction and fractures. Dutch cohort data in 2,468 courses documented insufficient replacement dosing and persistent anemia in 65% of cases, hinting that clinicians sometimes under-dose to mitigate adverse events. FDA guidance requires 30-minute post-infusion observation across the class, slowing clinic workflow. Collectively, these safety flags push some prescribers toward lower-dose or alternative complexes, capping near-term adoption of the highest-strength SKUs.

Other drivers and restraints analyzed in the detailed report include:

• Rapid Expansion of Outpatient Infusion Centers and Dialysis Networks Worldwide
• Updated International Guidelines Endorsing IV Iron as First-Line Therapy in CKD And Heart Failure
• Intensifying Generic Competition Driving Price Erosion in Mature Molecules

Segment Analysis

Ferric carboxymaltose held 44.78% of 2025 sales, securing the largest intravenous iron drugs market share on the back of extensive evidence across CKD and HF protocols. However, the intravenous iron drugs market size for iron isomaltoside is forecast to post a 10.14% CAGR to 2031 as prescribers value its lower hypophosphatemia risk profile. The PHOSPHARE-IBD study estimated that derisomaltose cuts infusion visits by 1.64 over a five-year horizon, translating into NOK 9,707 cost savings per patient.

Momentum toward safety-led selection continues. Sucrose enjoys embedded use in dialysis bundles, whereas sodium ferric gluconate fills niche hypersensitivity cases. Ferumoxytol’s generic entry exerts pricing leverage across the class, triggering formulary shifts. Overall, differentiated safety, dosing convenience and cost shape the competitive axis more than simple brand tenure.

CKD accounted for 51.62% of revenue in 2025, underpinned by obligatory iron needs within hemodialysis protocols. Yet the intravenous iron drugs market will increasingly pivot toward HF, where the indication’s 10.02% CAGR reflects landmark trials showing 18% reductions in composite cardiovascular endpoints. Reimbursement updates in Europe now cover outpatient HF infusions, widening addressability.

Oncology, IBD and obstetric segments deliver incremental volume through recognition of functional iron deficiency unresponsive to oral therapy. Precision screening of transferrin saturation in bariatric surgery further elevates demand. The indication mix continues to diversify, distributing growth more evenly beyond traditional nephrology silos.

Complete Report Scope:

• By Product Type
  • Ferric Carboxymaltose
  • Iron Sucrose
  • Intravenous Ferumoxytol
  • Sodium Ferric Gluconate Complex
  • Iron Isomaltoside 1000
  • Other Product Type
• By Indication
  • Chronic Kidney Disease (Dialysis & Non-Dialysis)
  • Inflammatory Bowel Disease
  • Cancer- & Chemotherapy-Induced Anemia
  • Obstetrics & Gynecology (Pregnancy-Related Anemia)
  • Heart Failure with Iron Deficiency
  • Bariatric & Gastrointestinal Surgery
  • Other Indications
• By End-User
  • Hospitals (In-patient)
  • Out-patient Infusion & Oncology Centers
  • Dialysis Centers
  • Other End-Users
• By Distribution Channel
  • Direct Tenders / Institutional Sales
  • Hospital Pharmacies
  • Online & Specialty Pharmacies
  • Captive Dialysis Service Providers
• Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • Middle East & Africa
    • GCC
    • South Africa
    • Rest of Middle East & Africa
  • South America
    • Brazil
    • Argentina
    • Rest of South America

Geography Analysis

North America contributed 42.05% of global turnover in 2025, sustained by guideline-driven uptake and broad reimbursement of parenteral iron. Independence Blue Cross’s step-edit rules exemplify mounting cost oversight, yet CMS’s reimbursement increase secures dialysis channel volume. Mature infrastructure supports stable demand, though unit growth is flattening as eligible CKD cohorts approach full penetration.

Asia-Pacific is forecast to record the fastest 9.42% CAGR through 2031, led by China’s volume-linked procurement that cut prices 42% while lifting usage 49%. Joint ventures such as CSL Vifor-Fresenius target more than 2,000 tier-3 hospitals, and India’s Anemia Mukt Bharat program seeks to narrow diagnostic gaps. Affordability remains a ceiling, yet economic expansion and insurance coverage gains support rising uptake.

Europe benefits from entrenched nephrology protocols and HF guideline alignment. However, high generic penetration and HTA scrutiny constrain price growth. Regulatory attention to fair competition - illustrated by the EU probe into disparagement claims - ensures diversified molecule availability. Middle East & Africa and South America show nascent but accelerating adoption as private insurers and public health funds recognize the productivity gains of rapid anemia correction.

List of Companies Covered in this Report:

• CSL Behring
• Daiichi Sankyo
• Sanofi
• Pharmacosmos
• Shield Therapeutics plc
• Covis Pharma
• Akebia Therapeutics Inc. (Keryx/AMAG)
• Rockwell Medical
• Pfizer
• Zydus Lifesciences Ltd.
• Fresenius
• Dr. Reddy’s Laboratories
• Emcure Pharmaceuticals
• Teva Pharmaceutical Industries
• Nichi-Iko Pharmaceutical Co. Ltd.
• Lupin
• FDC Ltd.
• Hikma Pharmaceuticals

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support